|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 29/00 | |
| A61P 3/00 | |||
| A61K 38/17 | |||
| A61L 31/16 | |||
| A61K 9/06 | |||
| A61L 27/00 | |||
| A61K 38/07 |
| (11) | Number of the document | 2504035 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10830687.9 |
| Date of filing the European patent application | 2010-11-10 | |
| (97) | Date of publication of the European application | 2012-10-03 |
| (45) | Date of publication and mention of the grant of the patent | 2019-03-27 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/056277 |
| Date | 2010-11-10 |
| (87) | Number | WO 2011/060104 |
| Date | 2011-05-19 |
| (30) | Number | Date | Country code |
| 25974809 P | 2009-11-10 | US |
| (72) |
MACKEL, Michael, John, US
PARK, John, US
|
| (73) |
Allegro Pharmaceuticals, LLC,
31103 Rancho Viejo Road, No. 2249, San Juan Capistrano, CA 92675,
US
|
| (54) | COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES |
| COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES |